TABLE 1 | Selected anti-obesity drugs in development
From the following article:
Irena Melnikova and David Wages
Nature Reviews Drug Discovery 5, 369-370 (May 2006)
doi:10.1038/nrd2037
| Drug | Company | Target/mechanism | Status |
|---|---|---|---|
| Appetite suppressants | |||
| Rimonabant (Acomplia) | Sanofi-Aventis | CB1 receptor | Approvable letter from FDA |
| APD356 | Arena Pharmaceuticals | 5-HT2C receptor | Phase IIb |
| Pramlintide/AC137 (Symlin) | Amylin Pharmaceuticals | Antiglycaemic agent (Synthetic analogue of human amylin) | Marketed for diabetes; Phase II for obesity |
| PYY3-36 | Nastech | NPY receptor | Phase I |
| PYY3-36 | Emisphere | NPY receptor | Phase I |
| AC 162352/PYY3-36 | Amylin Pharmaceuticals | NPY receptor | Phase I |
| Oxyntomodulin | Thiakis | Regulation of the appetite circuits in the hypothalamus | Phase I |
| TM 30338 | 7TM Pharma | NPY2 and NPY4 receptors | Phase I/II |
| Anti-ghrelin vaccine | Cytos Biotechnology | Ghrelin | Phase I/IIa |
| Nutrient-absorption inhibitors | |||
| Cetilistat (ATL-962) | Alizyme | Lipases | Phase II |
| GT 389-255 | Peptimmune | Pancreatic lipases | Phase I |
| AOD 9604 (hGH 177-191) | Metabolic Pharmaceuticals | Increased metabolism (peptide of human growth hormone) | Phase IIb |
| Oleoyl-estrone (OE) | Manhattan Pharmaceuticals | Induces adipose tissue wasting and lowers appetite | Phase I |
Download file
If the slide opens in your browser, select "File > Save As" to save it.
